Increased aldosterone levels in a model of type 2 diabetes mellitus

Experimental and Clinical Endocrinology and Diabetes

Volumn 117, Issue 1, 2009, Pages 15-20

  Fredersdorf, S ^a   Endemann, D H ^a   Luchner, A ^a   Heitzmann, D ^a   Ulucan, C ^a   Birner, C ^a   Schmid, P ^a   Stoelcker, B ^a   Resch, M ^a   Muders, F ^a   Riegger, G A J ^a   Weil, J ^a,b  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Aldosterone; Diabetes type 2; Rat

Indexed keywords

ALBUMIN; ALDOSTERONE; ALDOSTERONE SYNTHASE; DIPEPTIDYL CARBOXYPEPTIDASE; GLUCURONIDE; LEPTIN RECEPTOR; MESSENGER RNA; POTASSIUM; RAMIPRIL; RENIN;

ALBUMINURIA; ALDOSTERONE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; ENZYME INHIBITION; INSULIN RESISTANCE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; URINARY EXCRETION; ZUCKER DIABETIC FATTY RAT;

ACTINS; ALBUMINURIA; ALDOSTERONE; ALDOSTERONE SYNTHASE; ANIMALS; BLOOD PRESSURE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; HEART RATE; MALE; RATS; RATS, ZUCKER; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 61849178070     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/s-2008-1073128     Document Type: Article

References (28)

1. Bentley-Lewis R, Adler GK Perlstein T, Seely EW, Hopkins PN, Williams GH, GargR. Body mass index predicts aldosterone production in normotensive adults on a high-salt diet. J Clin Endocrinol Metab 2007; 92:4472-4475
2. Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation 2007; 26 (115): 3213-3223
3. Cha DR, Kang YS, Han SY, Jee YH, Han KH, Kim HK, Han JY, Kim YS. Role of aldosterone in diabetic nephropathy. Nephrology 2005; 10 (Suppl): S37
4. Cooper ME. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 1998; 352: 213-219
5. Cronin CC, Barry D, Crowley B, Ferriss JB. Reduced plasma aldosterone concentrations in randomly selected patients with insulin-dependent diabetes mellitus. Diabet Med 1995 ; 12: 809 - 815
6. Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A, Langenbach J, Willenbeg HS, Barthel A, Hauner H, MacCann SM, Scherbaum W, Bornstein SR. Human adipocytes secrete mineralocorticoid-releasing factors. PNAS 2003; 100: 14211-14216
7. Endemann DH, Touyz RM, Iglarz M, Savoia C, Schiffrin EL. Eplerenone prevents salt-induced vascular remodeling and cardiac fibrosis in stroke-prone spontaneously hypertensive rats. Hypertension 2004;43 : 1252 - 1257
8. Engeli S, Bohnke J, Gorzelniak K, Janke J, Schling P, Bader M, Luft FC, Sharma AM. Weight loss and the renin-angiotensin-aldosterone system. Hypertension 2005 ; 45 : 356 - 362
9. Fredersdorf S, Thumann C, Ulucan C, Griese DP, Luchner A, Riegger GA, Kromer EP, Weil J. Myocardial hypertrophy and enhanced left ventricular contractility in Zucker diabetic fatty rats. Cardiovasc Pathol 2004 ; 13 : 11 - 19
10. Fredersdorf S, Weil J, Ulucan C, Birner C, Büttner R, Schubert T, Boger CA, Debl K, Muders F, Riegger GA, Luchner A. Vasopeptidase inhibition attenuates proteinuria and podocyte injury in Zucker diabetic fatty rats. Naunyn Schmiedebergs Arch Pharmacol 2007; 375 :95 - 103
11. Fujiwara K, Hayashi K, Matsuda H, Kubota E, Honda M, Ozawa Y, Saruta T. Altered pressure-natriuresis in obese Zucker rats. Hypertension 1999; 33: 1470-1475
12. Hollenberg NK, Stevanovic R, Agarwal A, Lansang MC, Price DA, Laffel LM, Williams GH, Fisher ND. Plasma aldosterone concentration in the patient with diabetes mellitus. Kidney Int 2004; 65:1435 - 1439
13. Huang TH, Yang Q, Harada M, Li GQ Yamahara J, Roufogalis BD, Li Y. Pomegranate flower extract diminishes cardiac fibrosis in Zucker diabetic fatty rats: modulation of cardiac endothelin-1 and nuclear fac-tor-kappaB pathways. J Cardiovasc Pharmacol 2005; 46: 856-862
14. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, Faire U De, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K, Lederballe-Pedersen O, Nieminen Ms, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapinn S. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359: 1004 - 1010
15. Luik PT, Kerstens MN, Hoogenberg K, Navis GJ, Dullaart RP. Low plasma aldosterone despite normal plasma renin activity in uncomplicated type 1 diabetes mellitus: effects of RAAS stimulation. Eur J Clin Invest 2003 ; 33: 787 - 793
16. Miric G, Dallemagne C, Endre Z, Margolin S, Taylor SM, Brown L. Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats. Br J Pharmacol 2001; 133: 687-694
17. Müller J. Regulation of aldosterone biosynthesis: the end of the road? Clin Exp Pharmacol Physiol Suppl 1998; 25 : S79 - 85
18. Nishikawa T, Suematsu S, Saito J, Soyama A, Ito H, Kino T, Chrousos G. Human renal mesangial cells produce aldosterone in response to low-density lipoprotein (LDL). J Steroid Biochem Mol Biol 2005; 96: 309-316
19. Peters B, Teubner P, Clausmeyer S, Puschner T, Maser-Gluth C, Wrede HJ, Kränzlin B, Peters J. StAR expression and the long-term aldosterone response to high-potassium diet in Wistar-Kyoto and spontaneously hypertensive rats. Am J Physiol Endocrinol Metab 2007; 292 :E16 - 23
20. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717
21. Pitt B, Remme W, Zannad F, Neaton J, MartinezF, Roniker B, Bittman R, Hurley S, Kleinman J, Gatlin M. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003 ; 348 :1309 -1321
22. Reddy SR, Kotchen TA. Dietary sodium chloride increases blood pressure in obese Zucker rats. Hypertension 1992 ; 20 : 389 - 393
23. Schafer S, Linz W, Afkam F. Treatment of hypertensive nephropathy by the novel vasopeptidase inhibitor AVE7688: nephroprotection beyond ACE- inhibition alone. Nephrol Dial Transplant 2003 ; 18 (Suppl. 4) : 601
24. Schafer S, Linz W, Vollert H, Biemer-Daub G, Rutten H, Bleich M, Busch AE. The vasopeptidase inhibitor AVE7688 ameliorates type 2 diabetic nephropathy. Diabetologia 2004; 47: 98- 103
25. Weber KT. Aldosterone in congestive heart failure. N Engl J Med 2001;345 : 1689 - 1697
26. Weil J, Zolk O, Griepentrog J, Wenzel U, Zimmermann WH, Eschenhagen T. Alterations of the preproenkephalin system in cardiac hypertrophy and its role in atrioventricular conduction. Cardiovasc Res 2006; 69 :412 - 422
27. Wotus C, Levay-Young BK, Rogers LM, Gomez-Sanchez CE, Engeland WC. Development of adrenal zonation in fetal rats defined by expression of aldosterone synthase and 11beta-hydroxylase. Endocrinology 1998; Oct: 139:4397-139:4403
28. Xue C, Siragy HM. Local renal aldosterone system and its regulation by salt, diabetes, and angiotensin II type 1 receptor. Hypertension 2005 ; 46 : 584 - 590